On Aug. 19, 2026, Moderna and Merck announced that their personalized vaccine, intismeran autogene, succeeded in reducing the recurrence of the skin cancer melanoma when combined with the immunotherapy drug Keytruda.
On Aug. 19, 2026, Moderna and Merck announced that their personalized vaccine, intismeran autogene, succeeded in reducing the recurrence of the skin cancer melanoma when combined with the immunotherapy drug Keytruda.
Don't miss out on today's news
